is a bacterial pathogen of global concern and is responsible for 10-15% of nosocomial infections worldwide. This opportunistic bacterial pathogen is known to cause serious complications in immunocompromised patients and is notably the leading cause of morbidity and mortality in patients suffering from cystic fibrosis. Currently, the only line of defense against infections is antibiotic treatment. Due to the acquired and adaptive resistance mechanisms of this pathogen, the prevalence of multidrug resistant strains has increased, presenting a major problem in healthcare settings. To date, there are no approved licensed vaccines to protect against infections, prompting the urgent need alternative treatment options. An alternative to traditional vaccines is vectored immunoprophylaxis (VIP), which utilizes a safe and effective adeno-associated virus (AAV) gene therapy vector to produce sustained levels of therapeutic monoclonal antibodies (mAbs) in vivo from a single intramuscular injection. In this review, we will provide an overview of biology and key mechanisms of pathogenesis, discuss current and emerging treatment strategies for infections and highlight AAV-VIP as a promising novel therapeutic platform.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775905 | PMC |
| http://dx.doi.org/10.3390/biomedicines10123162 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of an F Protein-Based Recombinant Protein for Immunization Against Respiratory Syncytial Virus.
Viral Immunol
January 2025
Department of Microbiology, Basic Science Center, Autonomous University of Aguascalientes, Aguascalientes, Mexico.
Respiratory syncytial virus (RSV) is one of the most important etiologies of acute respiratory infections that cause bronchiolitis in children under 5 years of age. Treatments are expensive, no vaccine is available, and this is an important cause of hospitalization. Costimulatory molecules have been reported to be good inducers of antiviral type 1 immune response.
View Article and Find Full Text PDFInvestigating the effectiveness of whole-virus, protein-based, and vector-based SARS-CoV-2 vaccines on the rates of COVID-19 infection, hospitalization, and mortality: a historical cohort study in Iran.
BMC Infect Dis
January 2025
Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Each of the Coronavirus disease 2019 (COVID-19) vaccines has its characteristics that can affect their effectiveness in preventing hospitalization and patient mortality. The present study aimed to determine the effectiveness of COVID-19 vaccines, including whole-virus, protein-based, and vector-based on COVID-19 infection, hospitalization, and mortality.
Methods: The current cohort study was conducted using the data of all people who received at least two doses of each type of COVID-19 vaccine from March 2020 to August 2022 in Khorasan Rzavi province.
Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.
Sci Rep
January 2025
Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine (LSHTM), Keppel Street, London, WC1E 7HT, UK.
During the COVID-19 pandemic, heterologous vaccination strategies were employed to alleviate the strain on vaccine supplies. The Thailand Ministry of Health adopted these strategies using vector, inactivated, and mRNA vaccines. However, this approach has introduced challenges for SARS-CoV-2 sero-epidemiology studies.
View Article and Find Full Text PDFMUC5B regulates alterations in the immune microenvironment in nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway.
Discov Oncol
January 2025
Department of Ear, Nose and Throat (ENT), The First People's Hospital of Jiande, No. 599 Yanzhou Avenue, Xin'anjiang Street, Jiande, 311600, Zhejiang, China.
Objective: To screen potential differentially expressed genes related to immune function in nasopharyngeal carcinoma through an online database, and to verify their mechanism of action, so as to provide a reference for the diagnosis and treatment of nasopharyngeal carcinoma in the future.
Methods: Differentially expressed genes were analyzed from the GSE227541 dataset, and functional enrichment analysis was conducted. With mucin 5B, oligomeric mucus/gel-forming as the focus, the correlation between its expression and immune indexes was analyzed by using the TIMER database.
Anti-Mesothelin CAR-NK cells as a novel targeted therapy against cervical cancer.
Front Immunol
January 2025
Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Resistance to the currently available treatment paradigms is one of the main factors that contributes to poor outcomes in patients with advanced cervical cancer. Novel targeted therapy approaches might enhance the patient's treatment outcome and are urgently needed for this malignancy. While chimeric-antigen receptor (CAR)-based adoptive immunotherapy displays a promising treatment strategy for liquid cancers, their use against cervical cancer is largely unexplored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!